3:44 PM
Jul 24, 2017
 |  BC Extra  |  Clinical News

Reata gains as bardoxolone study moves to Phase III

Reata Pharmaceuticals Inc. (NASDAQ:RETA) gained $4.37 (14%) to $35.47 on Monday after saying it will move ahead to the Phase III portion of the Phase II/III CARDINAL study of bardoxolone methyl (RTA 402) to treat chronic kidney disease (CKD) caused by Alport syndrome.


Read the full 206 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$50 USD
More Info >